Table 2.
Histopathological diagnosis of the 311 brain biopsies
| Neuropathological diagnosis | n (%) | |
|---|---|---|
| Primary glial brain tumor | 145 (46.6) | |
| Glioblastoma WHO IV | 69 | |
| Anaplastic astrocytoma WHO III | 36 | |
| Diffuse astrocytoma WHO II | 36 | |
| Diffuse midline glioma WHO IV | 4 | |
| Molecular diagnosis in glioma patients | IDH status obtained | 121 (83.4) |
| Wildtype | 100 | |
| Mutated | 21 | |
| MGMT status obtained* | 90 (82.6) | |
| MGMT unmethylated* | 41 | |
| MGMT methylated* | 49 | |
| 1p/19q codeletion status obtained | 11 (7.6) | |
| 1p/19q codeletion | 0 | |
| Lymphoma | 51 (16.4) | |
| Primary CNS lymphoma (DLBCL) | 45 | |
| Secondary CNS lymphoma | 6 | |
| Other tumors | 9 (2.9) | |
| Metastasis | 4 | |
| Histiocytosis | 2 | |
| Germial tumor | 2 | |
| Meningioma | 1 | |
| Vascular | 18 (5.8) | |
| Vasculitis | 6 | |
| Old hemorrhage/infarction | 10 | |
| Amyloid angiopathy | 2 | |
| Inflammatory (infectious) | 30 (9.6) | |
| Abscess | 19 | |
| PML | 4 | |
| Opportunistic infection | 1 | |
| Encephalitis | 6 | |
| Inflammatory (autoimmune) | 15 (4.8) | |
| CNS degenerative diseases | 8 | |
| Encephalitis | 7 | |
| Non-diagnostic | Unspecific reactive changes | 43 (13.8) |
PML, progressive multifocal leukoencephalopathy; CNS, central nervous system; MGMT, O6-methylguanine–DNA methyltransferase; DLBCL, diffuse large B cell lymphoma; IDH, isocitrate dehydrogenase
“*” refers only to high-grade gliomas (n = 109)